The global oral solid dosage pharmaceutical market was valued at US$ 524.6 billion in 2021 and is expected to top US$ 1.03 trillion in value by the end of 2032, expanding rapidly at a CAGR of 6.4% over the 2022-2032 study period. Oral solid dosage pharmaceuticals are final medication products that are consumed orally, broken down in the digestive tract, and then absorbed into the bloodstream. Oral solid doses are less expensive and simpler to produce than other dosage forms. They also provide important advantages such as trouble-free transport, packaging, and greater chemical & physical stability.
Low production cost is also contributing to market growth, especially in developing nations such as India due to collaborations with small-scale and medium-scale manufacturers. The production cost of oral solid dosage pharmaceuticals is low in India due to low and competitive land rates, availability of cheap labor, low-cost utilities, and affordable equipment. In developing regions, the labor cost is approximately 60% lower than in developed countries.
Download a Sample Copy of This Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=7553?PJ
Key findings of the Oral Solid Dosage Pharmaceutical market study:
- The report provides a present market outlook on Oral Solid Dosage Pharmaceutical. Additionally, the Oral Solid Dosage Pharmaceutical market share is anticipated to grow with a CAGR of 6.4% in the forecast period.
- Regional breakdown of the Oral Solid Dosage Pharmaceutical market based on predefined taxonomy.
- Innovative manufacturing processes implemented by Oral Solid Dosage Pharmaceutical vendors in detail.
- Region-wise and country-wise fragmentation of the Oral Solid Dosage Pharmaceutical market to grasp the revenue, and growth outlook in these areas.
- Changing preferences among consumers across various regions and countries.
- Factors (Positive and Negative) impacting the growth of the global Oral Solid Dosage Pharmaceutical market.
- Oral Solid Dosage Pharmaceutical price, market share, and Trends forecast for assessment period 2022-2032
What is the U.S. Market Stance for Oral Solid Dosage Pharmaceuticals?
Due to the rising number of oral solid dosage medication approvals in the U.S., the country had 93.6% of the North American oral solid dosage pharmaceutical market share in 2021. The U.S. is a high revenue-generating nation since FDA approvals are rising and leading to more items being marketed.
- For instance, in 2019, the Food and Drug Administration (FDA) of the United States approved 48 new medications.Oral solid dose medicines made up 54% of the new pharmaceuticals that the FDA has authorised. In pill form, it was 19; in capsule form, it was 7.
Additionally, the U.S. market for oral solid dose medicines is presented with attractive potential by the growing popularity of health supplements, which are often in the form of tablets or capsules.
Competitive landscape analysis
By obtaining clearance for their new goods and forming alliances with top businesses, major makers of pharmaceutical oral solid dosage products are actively focused on the extension of their portfolios.
- The EU authorities gave AstraZeneca permission to commercialise Evusheld long-acting antibody combos in March 2022 in order to prevent COVID-19 in a large population.
- Bristol Myers Squibb stated in June 2022 that it has signed a binding merger agreement to acquire Turning Point Therapeutics. Because Turning Point Therapeutics is a precision oncology firm in the clinical stages, this purchase will enhance BMS’s offering of cancer medications.
Some of the leading companies operating in the market are :
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences
- Merck & Co. Inc
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- Boehringer Ingelheim GmbH
- Hoffman-La-Roche Ltd.
- Johnson & Johnson
- Biogen Inc.
- Bayer AG
- Teva Pharmaceuticals
- Amgen Inc.
- Takeda Pharmaceutical Company Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Astellas Pharma Inc.
- Others
Key Segments in Oral Solid Dosage Pharmaceutical Industry Research
· By Dosage Form :
- Tablets
- Conventional/Immediate Release
- Modified Release
- Chewable Tablets
- Effervescent Tablets
- Capsules
- Hard Gelatin Capsules
- Soft Gelatin Capsules
- Others
- Powders & Granules
- Lozenges & Pastilles
- Gummies
· By Drug Release Mechanism :
- Immediate Release
- Delayed Release
- Controlled Release
· By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
- Hypermarkets / Supermarkets
· By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)